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for analyses. Median age at transplant was 29 (range, 0-76).
58% received stem cells from related donors. 78% received
bone marrow, 14% received peripheral blood stem cell, and
8% received cord blood. 77% received myeloablative condi-
tioning. Median follow-up for survivors was 7 years (range, 2
to 28). A total of 57,766 person-years were observed. 6,884
recipients were followed for more than 5 years (32,438
person years for observation period of 5 years or longer).
Standarized mortality ratio (observed / expected ratio) was
calculated for comparison with general population in Japan
for speciﬁc causes of death.
Results: Among relapse-free survivors at 2 years, overall
survival at 10 years, 15years were 86%, and 82%. Probabilities
were 95% and 91% when subjects were limited to relapse-
free survivors at 5 years. When compared to general pop-
ulation in Japan, risk of overall mortality was signiﬁcantly
higher (observed / expected ratio [O/E] ¼ 15.1, 95%CI, 14.3-
16.0). The risk of mortality was signiﬁcantly higher with
infection (O/E¼89.8, 95%CI, 77.4-100.7), new malignancy (O/
E¼3.2, 95%CI, 2.6-4.0), cardiovascular (O/E¼2.3, 95%CI, 1.5-
3.5), respiratory (O/E¼150.9, 95%CI, 131.1-172.5) including
chronic obstructive lung disease (O/E¼182.2, 95%CI, 101.2-
214.1), digestive (O/E¼4.2, 95%CI, 1.4-9.7), liver (O/E¼10.5,
95%CI, 7.4-14.8), kidney-genitourinary (O/E¼23.6, 95%CI,
13.1-37.1), and external cause (O/E¼2.5, 95%CI, 1.5-3.8)
compared to general population. The risk of death from any
cause was approximately twenty times higher from 2 to 4
years after transplant for relapse-free survivors at 2 years (O/
E¼21.1, 95%CI, 19.6-22.6) compared to general population.
The risk was still ten times higher with statistical signiﬁcance
for the subjects after 5 years post transplant (O/E¼10.0, 95%
CI, 9.1-11.0).
Conclusions: Long-term survivors after allogeneic HCTare at
higher risk of mortality due to various causes other than
underlying diseases. Screening and preventive practices are
important for long-term follow up of HCT recipients.75
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Late onset non-infectious pulmonary injury complicates
>10% of allogeneic stem cell transplants (SCT), particularly in
subjects conditioned with high dose Total Body Irradiation
(TBI), and contributes to transplant related mortality. To
characterize the kinetics of recovery from pulmonary injury
in long term survivors we collected data on 138 (78 male, 60
female) subjects surviving>5 years after SCT from their HLA-
matched siblings. The median age at transplant was 36 years.
Transplant indications were CML (63), AML (31), MDS (19),
ALL (12) and others (14). 126 subjects received 1200 cGy
TBI-based conditioning with or without lung shielding, 3
received 400 cGy TBI-based conditioning and 9 patients
received no irradiation. Ex vivo T cell depleted grafts were
given to 131 recipients, except for six who received a non-
myeloablative SCT. Of the 138 long term survivors, 26 had no
cGvHD, 70 had cGvHD lasting less than 3 years; and 42 had
prolonged cGvHD requiring systemic immunosuppression
for> 3 years. Among the 17 patients who died after 5 years, 4died of pulmonary causes, including two with lung cancer.
Pre-transplant abnormalities (< 80% predicted) in PFTs were
found in 15.9% of subjects in the following declining
frequency: FVC%, VC, TLC, FEV1, DLCO_Adj (adjusted for
hemoglobin and alveolar ventilation) Hb/VA and FEV1/FVC.
Baseline (BL) PFTs served as the reference for all subsequent
measurements at 3, 5, 10 and 15 years for each survivor. The
only parameter showing a clinically signiﬁcant decline post
transplant was DLCO_Adj which reached a nadir at 5 years,
with subsequent normalization at the 10 yearmark [paired t-
test]. An abnormal (<80% of baseline) DLCOAdj was found in
19.6, 21.0, 0.7 and 0% of survivors at 3, 5, 10 and 15 years. The
mean DLCO_Adj at 3, 5, 10 and 15 years were 91% (P ¼ .003),
88% (P < .001), 98% (p¼NS) and 100% (p¼NS) of BL, respec-
tively. Multivariable modeling (forward-stepwise multiple
regression) identiﬁed the presence of chronic GVHD
(P ¼ .017) and abnormal Baseline DLCO_Adj (P ¼ .023) as the
only signiﬁcant factors associated with the decline in
DLCO_Adj at 5 years but excluded smoking, conditioning
intensity, baseline C-reactive protein level, TBI dose to the
lungs and demographic variables. In conclusion, DLCO_Adj is
the only PFT marker associated with pulmonary injury in our
TBI-conditioned transplant population. DLCO_Adj nadirs at 5
years post-SCT, and normalizes by 10 years. Chronic GVHD
and pre-transplant DLCO_Adj are important contributory
factors to the decline in DLCO_Adj.76
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Background: Several recent studies have examined the use
of sirolimus (SIR) and tacrolimus (TAC) for prevention of
graft-versus-host disease (GVHD). Data are sparse, however,
regarding patient-reported quality of life (QOL) associated
with this regimen. We report an analysis of QOL outcomes in
the ﬁrst year post-transplant from a randomized controlled
trial of (SIR/TAC) compared to methotrexate (MTX)/TAC.
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patients randomized to SIR/TAC received one year of SIR
following HCT, while MTX/TAC patients received MTX on
days 1, 3, 6, and 11. QOL was assessed with the Functional
Assessment of Cancer Therapy e Bone Marrow Transplant
Treatment Outcome Index (TOI) prior to HCT and day 30, 90,
180, 270, and 360 following HCT. Random effects models
were used to examine longitudinal trajectories of QOL
between day 30 and 360 by study arm, controlling for
baseline TOI scores.
Results: A total of 74 patients were enrolled (37 per study
arm); all contributed data to these analyses. Analyses indi-
cated that the MTX/TAC group showed greater improvement
in TOI scores over time compared to the SIR/TAC group
(P ¼ .02); by day 360, the average difference between groups
was 7.18 points (P ¼ .03). This effect continued to be signiﬁ-
cant (P < .01) when controlling for clinical differences
between groups, including acute GVHD, chronic GVHD, and
anemia. Exploratory analyses of subscales comprising the
TOI [i.e., Physical Well-Being (PWB), Functional Well-Being
(FWB), BMT Scale (BMTS)] indicated that group differences
were due to greater improvement in PWB in the MTX/TAC
group (P ¼ .02). Additional exploratory analyses of items on
the PWB scale indicated that members of the SIR/TAC arm
were more likely to endorse a lack of energy and nausea over
time (ps.01). Study arm differences on these items per-
sisted when controlling for acute GVHD, chronic GVHD, and
anemia (ps<.01).
Conclusions: Data from the current study indicate that SIR/
TAC is associated with less improvement in QOL in the ﬁrst
year post-HCT compared to MTX/TAC. This difference is not
attributable to other potential clinical differences between
study arms, including acute and chronic GHVD and anemia.
Differences in QOL appear to result in part from greater
fatigue and nausea in participants treated with SIR, which
was administered throughout the one year follow-up period.77
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Background: Characterisation of late effects in children
undergoing hematopoietic stem cell transplant (HSCT) for
non-malignant diseases is challenging due to the small
numbers of rare diseases, variations in cancer susceptibility
and organ toxicity associated with primary diagnosis as well
as non-uniform clinical practice. In addition, limited follow-
up in previous studies may have underestimated the risk of
second cancers and late deaths in this group of transplant
recipients. Our study used population-based registry data to
determine the risk of malignancy and late mortality inpediatric patients transplanted for non-malignant
conditions.
Methods: 318 Australian allogeneic transplant recipients
aged less than 15 years, treated from 1982-2007 for non-
malignant conditions, were identiﬁed from children's
hospitals and the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR). Clinical and demographic data
were obtained from the ABMTRR and medical records.
Linkage with the Australian Cancer Database and National
Death Index was performed to identify all primary invasive
cancers and deaths in this cohort. Standardised incidence
ratios (SIRs) were generated for second malignancies and
deaths in 2-year survivors.
Results: Indications for HSCT included; primary immuno-
deﬁciencies (n¼130), aplastic anemia (SAA, n¼71), inherited
marrow failure syndromes (n¼51), thalassemia (n¼14) and
hemophagocytic lymphohistiocytosis (n¼14). Over two
thirds of recipients weremale (69%), while the median age at
transplant was 3 years (range 0-14y) A total of 43 patients
received radiation therapy as part of their conditioning
regimen.
Six malignancies were identiﬁed in male patients with
various diseases including Fanconi Anemia (2), Severe
Aplastic Anemia (1), severe combined immune deﬁciency
(1), Thalassemia (1) and chronic granulomatous disease
(n¼1). The most common second cancer was squamous cell
carcinoma of the tongue. Overall there was a 15-fold
increased risk of malignancy compared to the Australian
general population (SIR¼15.37, 95%CI¼6.91-34.21).
Two thirds of patients (62%) survived for more than 2
years after HSCT, while the cumulative incidence of late
death was 2.1% at 5 years from HSCT and 6.3% at 10 years
from HSCT. Overall, the rate of death was 17 times greater
than expected compared to the general population, with
cancer being the most common cause of death.
Conclusion: These ﬁndings show an increased rate of
malignancy and late death in Australian pediatric patients
transplanted for non-malignant conditions compared to the
general population. This conﬁrms the need for long term
surveillance to maximize the early detection of subsequent
malignancies, which may occur a decade or more after
HSCT.78
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Background: Increasing indications for transplant and
improvements in early transplant outcomes have lead to an
